About Comanche Biopharma
Comanche Biopharma is a private company based in Concord, Massachusetts, incorporated in 2020 in Delaware. It has reported $73,600,007 raised in two offerings on Form D since May 2023. Its chief executive is Thomas Johnson.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Dec 14, 2023 | Jan 17, 2024 | $37,500,000of $75.0M target | 7 | $5.3M | EquityRule 506(b) | Form D ↗ |
| Jun 28, 2021 | May 12, 2023 | $36,100,007fully sold | 7 | $5.1M | EquityRule 506(b) | Form D ↗ |
| Total, two offerings | $73,600,007 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Comanche Biopharma's Form D filed Jan 17, 2024.
AT
Ann Taylor
Director
BS
Brendan Bulik-Sullivan
Director
MM
Muzammil Mansuri
Director
AA
Allison August
Executive officer
PA
Paul Antinori
Executive officer
AF
Allyson Felix
Director
DG
David Grayzel
Director
TJ
Thomas Johnson
Chief Executive Officer and director
SG
Scott Gottlieb
Director
KP
Ketan Patel
Director
MY
Michael Young
Executive officer
Earlier filings also listed Clive Meanwell (director, last listed May 2023) and Arthur Levin (director, last listed May 2023).